Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributor.authorRosas-Umbert, Miriam-
dc.contributor.authorRuiz-Riol, Marta-
dc.contributor.authorFernández, Marco A.-
dc.contributor.authorMarszalek, Marta-
dc.contributor.authorColl, Pep-
dc.contributor.authorManzardo, Christian-
dc.contributor.authorCedeño, Samandhy-
dc.contributor.authorMiró Meda, José M.-
dc.contributor.authorClotet i Sala, Bonaventura-
dc.contributor.authorHanke, Tomás-
dc.contributor.authorMoltó, José-
dc.contributor.authorMothe, Beatriz-
dc.contributor.authorBrander, Christian-
dc.description.abstractRomidepsin (RMD) is a well-characterized histone deacetylase inhibitor approved for the treatment of cutaneous T-cell lymphoma. in vitro and in vivo studies have demonstrated that it is able to induce HIV-1 gene expression in latently infected CD4+ T cells from HIV-1+ individuals on suppressive antiretroviral therapy. However, in vitro experiments suggested that RMD could also impair T-cell functionality, particularly of activated T cells. Thus, the usefulness of RMD in HIV-1 kick&kill strategies, that aim to enhance the immune system elimination of infected cells after inducing HIV-1 viral reactivation, may be limited. In order to address whether the in vitro observations are replicated in vivo, we determined the effects of RMD on the total and HIV-1-specific T-cell populations in longitudinal samples from the BCN02 kick&kill clinical trial (NCT02616874). BCN02 was a proof-of-concept study in 15 early treated HIV-1+ individuals that combined MVA.HIVconsv vaccination with three weekly infusions of RMD given as a latency reversing agent. Our results show that RMD induced a transient increase in the frequency of apoptotic T cells and an enhanced activation of vaccine-induced T cells. Although RMD reduced the number of vaccine-elicited T cells secreting multiple cytokines, viral suppressive capacity of CD8+ T cells was preserved over the RMD treatment. These observations have important implications for the design of effective kick&kill strategies for the HIV-1 cure.-
dc.format.extent11 p.-
dc.publisherFrontiers Media-
dc.relation.isformatofReproducció del document publicat a:
dc.relation.ispartofFrontiers in Immunology, 2020, vol. 11, num. 418-
dc.rightscc-by (c) Rosas-Umbert, Miriam et al., 2020-
dc.subject.classificationCèl·lules T-
dc.subject.otherT cells-
dc.titleIn vivo effects of romidepsin on T-Cell activation, apoptosis and function in the BCN02 HIV-1 kick&Kill clinical trial-
Appears in Collections:Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer)
Articles publicats en revistes (Medicina)

Files in This Item:
File Description SizeFormat 
701138.pdf1.13 MBAdobe PDFView/Open

This item is licensed under a Creative Commons License Creative Commons